Cargando…
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan
INTRODUCTION: Persistence with antipsychotic treatment is critical in managing patients with schizophrenia. To evaluate whether aripiprazole long-acting injection (aripiprazole once-monthly, AOM) can contribute to longer treatment persistence compared with daily orally administered aripiprazole (OA)...
Autores principales: | Iwata, Nakao, Inagaki, Ataru, Sano, Hiromi, Niidome, Kazunari, Kojima, Yoshitsugu, Yamada, Sakiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314731/ https://www.ncbi.nlm.nih.gov/pubmed/32500455 http://dx.doi.org/10.1007/s12325-020-01396-w |
Ejemplares similares
-
Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020) -
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post‐hoc analysis of a long‐term open‐label study
por: Ishigooka, Jun, et al.
Publicado: (2021) -
Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016) -
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023) -
Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)